Monthly Prescribing Reference

Opdivo + Yervoy Approved as First-Line Tx for MSI-H/dMMR Metastatic Colorectal Cancer

The risk of disease progression or death was reduced by 79% with nivolumab/ipilimumab compared with chemotherapy. The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in ...
MedPage Today on MSN

Regimen Improves PFS in Highly Mutated Metastatic Colorectal Cancer

Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the ...
Monthly Prescribing Reference

Nivolumab + Ipilimumab Under Review for First-Line Treatment of MSI-H/dMMR mCRC

A Prescription Drug User Fee Act target date of June 23, 2025 has been set for the application. The sBLA is supported by data from the randomized, open-label phase 3 CheckMate 8HW trial ...
Medscape

FDA Approves Nivolumab + Ipilimumab for Certain Patients With CRC

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for the treatment of adults and children aged 12 years ...
Healio

VIDEO: Trial builds on current microsatellite instability-high colorectal cancer therapy

Please provide your email address to receive an email when new articles are posted on . In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ...
Seeking Alpha

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High ...

Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in the risk of disease progression or death by 79% vs. chemotherapy in the first-line setting and by 38% vs. Opdivo ...
Nature

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Medical Xpress

Recurrence-free survival longer with nivolumab than ipilimumab in melanoma: Study

For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ipilimumab, according to a study published online Oct. 18 in the New England ...
Healio

Nivolumab maintains benefits over ipilimumab for advanced melanoma after lengthy follow-up

Please provide your email address to receive an email when new articles are posted on . Nivolumab significantly improved RFS for advanced melanoma compared with ipilimumab after 9 years of follow-up.
The American Journal of Managed Care

Nivolumab With Ipilimumab Approved by FDA for Use in Hepatocellular Carcinoma

The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved median ...
Medscape

FDA OKs First-line Nivolumab + Ipilimumab in Advanced HCC

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) as a first-line treatment for adults with unresectable or ...